View in EDS PDF Full Text

Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.

Saved in:
Bibliographic Details
Title: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.
Authors: Replogle JM; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Bonnar JL; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Pogson AN; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Liem CR; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Maier NK; Department of Microbiology, Harvard Medical School, Boston, United States., Ding Y; Department of Microbiology, Harvard Medical School, Boston, United States., Russell BJ; Department of Microbiology, Harvard Medical School, Boston, United States., Wang X; Department of Microbiology, Harvard Medical School, Boston, United States., Leng K; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States., Guna A; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States., Norman TM; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Pak RA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States., Ramos DM; Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, United States.; National Institute on Aging, National Institutes of Health, Bethesda, United States., Ward ME; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States., Gilbert LA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.; Arc Institute, Palo Alto, United States., Kampmann M; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States.; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States., Weissman JS; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States., Jost M; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Microbiology, Harvard Medical School, Boston, United States.
Source: ELife [Elife] 2022 Dec 28; Vol. 11. Date of Electronic Publication: 2022 Dec 28.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36576240
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Replogle+JM%22">Replogle JM</searchLink>; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.<br /><searchLink fieldCode="AU" term="%22Bonnar+JL%22">Bonnar JL</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.<br /><searchLink fieldCode="AU" term="%22Pogson+AN%22">Pogson AN</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.<br /><searchLink fieldCode="AU" term="%22Liem+CR%22">Liem CR</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.<br /><searchLink fieldCode="AU" term="%22Maier+NK%22">Maier NK</searchLink>; Department of Microbiology, Harvard Medical School, Boston, United States.<br /><searchLink fieldCode="AU" term="%22Ding+Y%22">Ding Y</searchLink>; Department of Microbiology, Harvard Medical School, Boston, United States.<br /><searchLink fieldCode="AU" term="%22Russell+BJ%22">Russell BJ</searchLink>; Department of Microbiology, Harvard Medical School, Boston, United States.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Department of Microbiology, Harvard Medical School, Boston, United States.<br /><searchLink fieldCode="AU" term="%22Leng+K%22">Leng K</searchLink>; Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States.; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States.<br /><searchLink fieldCode="AU" term="%22Guna+A%22">Guna A</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.<br /><searchLink fieldCode="AU" term="%22Norman+TM%22">Norman TM</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.<br /><searchLink fieldCode="AU" term="%22Pak+RA%22">Pak RA</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.<br /><searchLink fieldCode="AU" term="%22Ramos+DM%22">Ramos DM</searchLink>; Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, United States.; National Institute on Aging, National Institutes of Health, Bethesda, United States.<br /><searchLink fieldCode="AU" term="%22Ward+ME%22">Ward ME</searchLink>; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States.<br /><searchLink fieldCode="AU" term="%22Gilbert+LA%22">Gilbert LA</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.; Arc Institute, Palo Alto, United States.<br /><searchLink fieldCode="AU" term="%22Kampmann+M%22">Kampmann M</searchLink>; Institute for Neurodegenerative Disease, University of California, San Francisco, San Francisco, United States.; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States.<br /><searchLink fieldCode="AU" term="%22Weissman+JS%22">Weissman JS</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States.; Whitehead Institute for Biomedical Research, Cambridge, United States.; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, United States.<br /><searchLink fieldCode="AU" term="%22Jost+M%22">Jost M</searchLink>; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.; Department of Microbiology, Harvard Medical School, Boston, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101579614%22">ELife</searchLink> [Elife] 2022 Dec 28; Vol. 11. <i>Date of Electronic Publication: </i>2022 Dec 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22eLife+Sciences+Publications%2C+Ltd%22">eLife Sciences Publications, Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101579614 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2050-084X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222050084X%22">2050084X </searchLink><i>NLM ISO Abbreviation: </i>Elife <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36576240
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.7554/eLife.81856
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Replogle JM
      – PersonEntity:
          Name:
            NameFull: Bonnar JL
      – PersonEntity:
          Name:
            NameFull: Pogson AN
      – PersonEntity:
          Name:
            NameFull: Liem CR
      – PersonEntity:
          Name:
            NameFull: Maier NK
      – PersonEntity:
          Name:
            NameFull: Ding Y
      – PersonEntity:
          Name:
            NameFull: Russell BJ
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Leng K
      – PersonEntity:
          Name:
            NameFull: Guna A
      – PersonEntity:
          Name:
            NameFull: Norman TM
      – PersonEntity:
          Name:
            NameFull: Pak RA
      – PersonEntity:
          Name:
            NameFull: Ramos DM
      – PersonEntity:
          Name:
            NameFull: Ward ME
      – PersonEntity:
          Name:
            NameFull: Gilbert LA
      – PersonEntity:
          Name:
            NameFull: Kampmann M
      – PersonEntity:
          Name:
            NameFull: Weissman JS
      – PersonEntity:
          Name:
            NameFull: Jost M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 12
              Text: 2022 Dec 28
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2050-084X
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: ELife
              Type: main
ResultId 1